People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cortexyme, Inc. | — | Pharmaceuticals | Series C | $111.5M | $72.0M | 2015 |
| 4D Molecular Therapeutics Inc | — | Biotechnology | Series C | $108.6M | $3.7B | 2015 |
Margi McLoughlin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Margi McLoughlin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ilan Zipkin | 1 | 6 |
| Una Ryan | 1 | 4 |
| Sharon Tetlow | 1 | 4 |
| Casey Lynch | 1 | 4 |
| Charles Ryan | 1 | 3 |
| Dirk Thye | 1 | 3 |
| Tony Yao | 1 | 3 |
| David Kirn | 1 | 2 |
| Roger Quy | 1 | 2 |
| Brendan Hannah | 1 | 1 |
| Rajiv Patni | 1 | 1 |
| Stephen A. Dominy | 1 | 1 |
| David A. Lamond | 1 | 1 |
| Ilan A. Zipkin | 1 | 1 |
| Roger A. Quy | 1 | 1 |
| Margi A. McLoughlin | 1 | 1 |
| Margi McLaughlin | 1 | 1 |
| David Kirn, M.D. | 1 | 1 |
| Peter Francis, M.D. | 1 | 1 |
| Hoyoung Huh, M.D., Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.